Author: crjfinlayson

PharmaCielo Increases Cannabis Cultivation Through External Contractor to Meet Market Demand for Medicinal Extracts Additional area under active cultivation expands PharmaCielo’s immediate footprint by 32 percent to 1.6 million square feet with further expansion pending grower license approval Company activates first external cultivation contract with

Enables PharmaCielo to produce and deliver psychoactive extracts as part of the extracts agreement the Company announced in January of this year, intended for the German market Enhances product development flexibility and will accelerate PharmaCielo’s strategic priority to expand beyond CBD oils and isolates to

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO (July 3, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTCQX: PCLOF) is pleased to announce that it has closed its previously announced “bought deal” offering (the “Offering“)

TORONTO (June 29, 2020) – PharmaCielo Ltd. (the “Company” or “PharmaCielo”) (TSXV:PCLO, OTCQX:PCLOF) is pleased to announce that it has filed a (final) short form prospectus with the securities regulatory authorities in British Columbia, Alberta, Ontario and Quebec in connection with its previously announced $4

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO (June 10, 2020) – PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (the “Company” or “PharmaCielo”) is pleased to announce that it has entered into an agreement with a syndicate of investment dealers led by

Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO, Canada and RIONEGRO, Colombia (November 25, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the